Study of Airflow Limitation in Non-Smoking Adults and Teens with Moderate to Severe Asthma
Evaluating Treatment Effects of Inhaled Corticosteroids and Bronchodilators
Led by Gelb, Arthur F., M.D. · Updated on 2023-10-26
60
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to understand the causes and sites of expiratory airflow limitation in people with moderate to severe persistent asthma who are stable, treated, and non-smokers. The study focuses on whether airflow limitation mainly occurs in large or small airways and how much is due to airway obstruction or loss of lung elastic recoil. Researchers will use markers like exhaled nitric oxide to assess airway inflammation and will also study lung changes during asthma flare-ups and stable periods, including detailed imaging and tissue analysis when available.
Participants will receive treatment with one of three inhaled corticosteroid and long-acting beta2-agonist combinations fluticasonesalmeterol, budesonideformoterol, or mometasoneformoterol, combined with tiotropium daily. For acute flare-ups, albuterol and ipratropium will be used as needed. The study includes measurements of lung function and quality of life questionnaires. Imaging such as high-resolution CT scans and optical coherence tomography will be performed to evaluate lung structure and detect emphysema.
During the study, participants will undergo tests including spirometry with special gas mixtures to locate airflow limitation and exhaled nitric oxide measurements to monitor inflammation over 20 to 60 days. Researchers will also analyze lung tissue from autopsies or transplants when available. The main outcomes include assessing airway inflammation, airflow limitation sites, lung elastic recoil loss, and the presence and extent of emphysema. The study runs until June 2027, with detailed evaluations during stable periods and exacerbations.
CONDITIONS
Brief Title
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
Research Team
A
Arthur F Gelb, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Current non-smoking status with less than 10 pack years smoking history
Stable asthma under treatment
Age between 12 and 95 years
Post 180 mcg albuterol use: FEV1/FVC ratio less than 70% and FEV1 less than 80% predicted
You will not qualify if you...
Pregnancy
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 20 to 60 days
Participants receive one of three long-acting beta 2 agonist plus corticosteroid inhaled medications and tiotropium daily. Acute exacerbations are treated with albuterol/ipratropium inhalations as needed. Lung function and asthma quality of life are monitored.
Visits during treatment period for lung function and quality of life assessments
Follow-up Monitoring
Duration - Up to 10 days post death or lung transplant for some participants
Participants are observed for airway inflammation, airflow limitation mechanisms, and dynamic hyperinflation using various assessments including expiratory flow volume curves and exhaled nitric oxide measurements.
Additional assessments may occur depending on participant status (e.g., lung transplant)
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Phase 4 Multicenter Study on Starting Airsupra in the Emergency Department to Improve Asthma Outcomes Compared to Usual Care
Study of Inflammatory Lung Diseases Including Asthma, COPD, Bronchiectasis, Cystic Fibrosis, PCD, and ILD to Understand Patient Characteristics and Improve Personalized Treatment
Phase 1 Randomized Study Comparing Pharmacokinetics of Two GSK5784283 Formulations in Healthy Adults by Injection
Evaluating Different Lung Function Tests Including Impulse Oscillometry for Diagnosing Asthma in Adults
Evaluating Two Doses of Glycopyrronium Inhaler Compared to Placebo with Budesonide and Formoterol in Children 4 to Under 12 Years with Asthma
Randomized Feasibility Study of Nocturnal CPAP Compared to Standard Care in Adults with Large Airway Collapse
Study to Assess Patient Characteristics and Outcomes in Asthma Across Different Severities in Real-World Care
A Cross-Sectional and Prospective Observational Study of Asthma Disease Burden and Control
Phase 3 Open-label Study to Assess Depemokimab as Add-on Treatment for Asthma with Type 2 Inflammation in Children Aged 6 to 11 Years
Evaluating Depemokimab as an Add-On Treatment for Adolescents and Adults with Type 2 Asthma at Risk of Exacerbations Compared to Placebo and Standard Care
Evaluating HB0056 Injection for Adults with Moderate to Severe Asthma
Randomized, Double-Blind, Placebo-Controlled Study of Safety and Effectiveness
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
In moderate-to-severe asthma patients monitoring exhaled nitric oxide during exacerbation is not a good predictor of spirometric response to oral corticosteroid.
Arthur F Gelb, Roxanna Moridzadeh, Deepak H Singh...
Unraveling the Pathophysiology of the Asthma-COPD Overlap Syndrome: Unsuspected Mild Centrilobular Emphysema Is Responsible for Loss of Lung Elastic Recoil in Never Smokers With Asthma With Persistent Expiratory Airflow Limitation.
Arthur F Gelb, Alfred Yamamoto, Eric K Verbeken...